Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$136.37

2.47 (1.84%)

, ALIOF

Actelion

$278.86

2.2092 (0.80%)

10:40
10/11/17
10/11
10:40
10/11/17
10:40

Battleground: Goldman says sell J&J, but Jefferies sees 'dividend machine'

This morning, Jefferies analyst Jeffrey Holford upgraded Johnson & Johnson (JNJ) to Buy as he believes its Pharmaceutical division will drive earnings per share growth and dividend momentum. This is the second upgrade of the Dow member's this week, as his peer at Wells Fargo also raised the stock's rating to Outperform, citing expectations for a reacceleration of the company's sales growth. However, not all are as bullish on Johnson & Johnson. Late last month, Goldman Sachs analyst Jami Rubin downgraded the stock to Sell. DIVIDEND 'MACHINE': In a research note to investors, Jefferies' Holford upgraded Johnson & Johnson to Buy from Hold and raised his price target on the shares to $157 from $145. The analyst pointed out that he believes the company's Pharma division is "under-modeled" by the street and will drive above consensus revenue and earnings per share growth, expecting the shares to re-rate to a 10% market premium. Multiple TIRADE pharma assets, as well as synergies from Actelion (ALIOF), will drive above consensus Pharma revenues, producing strong earnings per share momentum and better than expected dividends, he added. Moreover, Holford argued that instead of commentators focusing on an unlikely break-up of the business, Johnson & Johnson should be appreciated for being an "EPS growth and dividend machine." ACCELERATION AHEAD: On Monday, Wells Fargo analyst Larry Biegelsen also upgraded Johnson & Johnson to Outperform from Market perform and raised his price target on the shares to $149 from $140. Citing the accretion from Actelion, more measured impact from biosimilar competition than expected, solid performance of key drugs and a pipeline that is coming to fruition, the analyst told investors that he believes the healthcare giant is poised to reaccelerate its top-line growth. Further, Biegelsen argued that the company could continue to deliver margin improvement and faster earnings per share growth, while noting that he sees several sources of potential earnings per share upside in 2018. Additionally, he pointed out that concerns over Zytiga patent risk may be overblown with generic competition unlikely until at least October 2018. SELL J&J: Back on September 20, however, Goldman Sachs' Rubin downgraded Johnson & Johnson to Sell, while increasing his price target to $130 from $125. The analyst argued that pressure on key products combined with still-slow Medical Devices & Diagnostics growth and continued strains on the consumer will leave the company with below average, long-term growth. Rubin added that he prefers names like AbbVie (ABBV), Bristol-Myers (BMY) and Eli Lilly (LLY) with more identifiable, needle moving catalysts. PRICE ACTION: In morning trading, shares of Johnson & Johnson have gained almost 2% to $136.25. Since September 20, the stock is up roughly 1%.

JNJ

Johnson & Johnson

$136.37

2.47 (1.84%)

ALIOF

Actelion

$278.86

2.2092 (0.80%)

ABBV

AbbVie

$91.91

0.74 (0.81%)

BMY

Bristol-Myers

$65.41

0.2841 (0.44%)

LLY

Eli Lilly

$86.17

0.01 (0.01%)

  • 11

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 23

    Oct

  • 24

    Oct

  • 26

    Oct

  • 27

    Oct

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

JNJ Johnson & Johnson
$136.37

2.47 (1.84%)

10/11/17
10/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying J&J's Pharma division is "under-modeled" by analysts and will drive above-consensus revenue and earnings growth. 2. Visa (V) and MasterCard (MA) were upgraded to Outperform from Market Perform at Wells Fargo. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. 4. AbbVie (ABBV) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week. 5. PayPal (PYPL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
10/09/17
10/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Larry Biegelsen saying J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition." 2. Morgan Stanley (MS) upgraded to Outperform from Neutral at Credit Suisse with analyst Susan Roth Katzke citing the over 10% total return potential in the shares. 3. Disney (DIS) upgraded to Top Pick from Outperform at RBC Capital with analyst Steven Cahall saying he thinks the company has reached a turning point with ESPN approaching less than 20% of earnings and "non-Media" Disney remaining a global leader in content that is executing well. 4. INC Research (INCR) upgraded to Buy from Hold at Jefferies analyst David Windley saying the recent share pullback provides a "compelling" entry point. 5. British American Tobacco (BTI) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/17
JEFF
10/11/17
UPGRADE
Target $157
JEFF
Buy
Johnson & Johnson upgraded to Buy from Hold at Jefferies
Jefferies analyst Jeffrey Holford upgraded Johnson & Johnson to Buy while raising his price target for the shares to $157 from $145. The healthcare giant closed yesterday up 36c to $133.90. J&J's Pharma division is "under-modelled" by analysts and will drive above-consensus revenue and earnings growth, Holford tells investors in a research note. He sees the company's TIRADE pharma assets, or Tremfya, Imbruvica, rivaroxaban, Apalutamide, Darzalex, Esketamine and Stelara, as well as synergies from the Actelion acquisition, driving strong earnings momentum and better than expected dividends. Holford expects J&J shares to re-rate to a 10% market premium.
ALIOF Actelion
$278.86

2.2092 (0.80%)

01/26/17
01/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cognex (CGNX) initiated with a Neutral at JPMorgan. 2. Realogy (RLGY) initiated with a Hold at Deutsche Bank. 3. EQT Midstream Partners (EQM) ande EQT GP (EQGP) were initiated with a Buy at Janney Capital. 4. Williams (WMB) was assumed with an Outperform at Credit Suisse, while Williams Partners (WPZ) was assumed with a Neutral. 5. Actelion (ALIOF) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/19/17
UBSW
04/19/17
NO CHANGE
Target $136
UBSW
Buy
Johnson & Johnson weakness a buying opportunity, says UBS
UBS analyst Matt Miksic believes Johnson & Johnson (JNJ) delivered a solid bottom line beat on in-line sales but prior period adjustments impacted Pharma growth, making the as-reported results look less robust. He raised his estimates to include the Actelion (ALIOF), deal which is expected to close in Q2. Miksic views the initial pullback in the stock as creating a particularly attractive entry point for investors. Miksic reiterated his Buy rating and $136 price target on Johnson & Johnson shares.
03/08/17
JPMS
03/08/17
UPGRADE
JPMS
Overweight
Actelion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded Actelion (ALIOF) to Overweight citing a "high confidence" that the Johnson & Johnson (JNJ) buyout will complete. The analyst sees 7% potential return by mid-2017.
01/31/17
01/31/17
NO CHANGE

Deutsche sees label warnings as worst case for Actelion drug
After France's National Agency for the Safety of Medicines and Health Products, in a letter dated January 24, asked doctors to stop treating new patients with Actelion's (ALIOF) Uptravi as it investigates patient deaths, Deutsche Bank said it believes a label warnings for the pulmonary arterial hypertension drug is likely the worst case scenario. The firm thinks Johnson & Johnson (JNJ) likely knew of the letter before reaching an agreement to acquire Actelion. Shares of Actelion are down 4% to $65.40 in morning trading.
ABBV AbbVie
$91.91

0.74 (0.81%)

10/09/17
WBLR
10/09/17
NO CHANGE
Target $110
WBLR
Outperform
AbbVie fair value estimate raised to $110 from $76 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for AbbVie to $110 to reflect progress with the pipeline and the recent Humira patent victory. The analyst now models Humira to maintain U.S. patent exclusivity through the end of 2022, extended from her previous estimate of 2020. Xu believes pivotal data readouts through year-end 2017 will continue to support the outperformance of AbbVie shares. She keeps an Outperform rating on the name.
10/11/17
COWN
10/11/17
UPGRADE
Target $105
COWN
Outperform
AbbVie upgraded to Outperform from Market Perform at Cowen
Cowen analyst Steve Scala upgraded AbbVie to Outperform and raised his price target for the shares to $105 from $95. AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week, Scala tells investors in a research note. He increased his out-year estimates for AbbVie after several of its drugs were highlighted during the conference. The stock is attractively valued versus the group overall, Scala argues.
10/09/17
LEER
10/09/17
NO CHANGE
LEER
Leerink not worried about JAK safety, AbbVie '494 profile so far 'ok'
Leerink analyst Geoffrey Porges notes that the delayed approval of Incyte (INCY)/Eli Lilly (LLY) baricitinib and the reported thromboembolic events in AbbVie's (ABBV) ABT494/upadacitinib trials have called into question the safety of oral Janus kinase, or JAK, inhibitors. The analyst says that his detailed review of the safety literature suggests that these medicines offer an acceptable risk/benefit profile for serious inflammatory diseases and do not confer a significant increase in cardiovascular risk or venous thromboembolic events. Further, Porges continues to believe AbbVie's upadacitinib and Gilead's (GILD) filgotinib will be approved for serious inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, and will capture the majority share of his peak risk-adjusted $12B estimated JAK market.
BMY Bristol-Myers
$65.41

0.2841 (0.44%)

09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.
10/06/17
UBSW
10/06/17
NO CHANGE
Target $72
UBSW
Buy
Bristol-Myers price target raised to $72 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Bristol-Myers to $72 from $62 to reflect higher product sales and flat operating expenses. The analyst also increased his sales for Opdivo given the failure of competitive drug trials and new uses for it in the head and neck setting. He believes Bristol-Myers remains the best positioned in immuno-oncology and at current prices offers a favorable risk/reward. Goodman reiterated his Buy rating on Bristol-Myers shares.
09/15/17
DBAB
09/15/17
NO CHANGE
Target $20
DBAB
Buy
Halozyme price target raised to $20 from $17 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme (HALO) to $20 saying he's bullish following the new Enhanze partnership. Yesterday's dual announcements for additional Enhanze collaborations are "clear positives" for the stock, Peters tells investors in a research note. He says the size of the Bristol-Myers Squibb deal, including the upfront payment, is larger than expected. The analyst reiterates a Buy rating on Halozyme.
09/15/17
JEFF
09/15/17
NO CHANGE
Target $72
JEFF
Buy
Bristol-Myers price target raised to $72 from $66 at Jefferies
Jefferies analyst Jeffrey Holford raised his price target for Bristol-Myers Squibb to $72 saying new opportunities for the Opdivo/Yervoy combo offer upside to estimates. The analyst says this, along with higher estimates for Eliquis and "significant" margin expansion over the mid term support his higher price target. Holford keeps a Buy rating on Bristol.
LLY Eli Lilly
$86.17

0.01 (0.01%)

10/10/17
FBCO
10/10/17
DOWNGRADE
Target $88
FBCO
Neutral
Eli Lilly downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Vamil Divan downgraded Eli Lilly to Neutral saying the valuation looks full with the shares up 13% since mid-August. The analyst sees limited drivers for further upside. He expects Lilly's sales growth to be flat in 2018 due to patent expiries, before returning to growth. Divan keeps an $88 price target for the shares. Lilly closed yesterday down 3c to $87.05.
10/10/17
10/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HSBC (HSBC) downgraded to Underperform from Neutral at Credit Suisse with analyst Sanjay Jain citing valuation. 2. Jabil Circuit (JBL) downgraded to Sell from Neutral at Goldman Sachs with analyst Mark Delaney saying street expectations, which assume Jabil's earnings grow double digits year-over-year for both of the next two years, are overly optimistic. 3. Carlyle Group (CG) downgraded to Neutral from Buy at Citi with analyst William Katz citing valuation with the shares up 60% year-to-date. 4. Eli Lilly (LLY) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying the valuation looks full with the shares up 13% since mid-August. 5. Ralph Lauren (RL) downgraded to Sell from Hold at Miller Tabak. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/17
BMOC
10/10/17
NO CHANGE
Target $73
BMOC
Underperform
Eli Lilly to have good Q3, but concerns remain for FY19-20, says BMO Capital
BMO Capital analyst Alex Arfaei says Eli Lilly will have a good Q3, ending FY17 at the top end of guidance. However, Arfaei contends that longer-term concerns remain warranted because of price and volume erosion for insulin drug Humulin and slower growth of type-2 diabetes drug Jardiance. The analyst maintains his Underperform rating on Eli Lilly, raising his price target to $73 from $71.

TODAY'S FREE FLY STORIES

OAS

Oasis Petroleum

$8.67

0.19 (2.24%)

05:28
10/17/17
10/17
05:28
10/17/17
05:28
Initiation
Oasis Petroleum initiated  »

Oasis Petroleum assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$165.01

-0.36 (-0.22%)

05:26
10/17/17
10/17
05:26
10/17/17
05:26
Recommendations
McDonald's analyst commentary  »

Nomura ups…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$48.09

0.23 (0.48%)

, QCOM

Qualcomm

$52.38

-0.44 (-0.83%)

05:26
10/17/17
10/17
05:26
10/17/17
05:26
Hot Stocks
Verizon, Qualcomm, Novatel Wireless to collaborate on 5G NR mmWave technology »

Verizon (VZ), Qualcomm…

VZ

Verizon

$48.09

0.23 (0.48%)

QCOM

Qualcomm

$52.38

-0.44 (-0.83%)

INSG

Inseego

$1.36

-0.03 (-2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

TYL

Tyler Technologies

$179.58

0.07 (0.04%)

05:21
10/17/17
10/17
05:21
10/17/17
05:21
Downgrade
Tyler Technologies rating change  »

Tyler Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ICUI

ICU Medical

$188.40

0.9 (0.48%)

05:20
10/17/17
10/17
05:20
10/17/17
05:20
Initiation
ICU Medical initiated  »

ICU Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

NFLX

Netflix

$202.68

3.19 (1.60%)

05:17
10/17/17
10/17
05:17
10/17/17
05:17
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

EQT

EQT Corporation

$62.56

-0.45 (-0.71%)

, RICE

Rice Energy

$27.32

-0.2 (-0.73%)

05:17
10/17/17
10/17
05:17
10/17/17
05:17
Hot Stocks
EQT Corporation reiterates benefits of pending acquisition of Rice Energy »

EQT Corporation (EQT),…

EQT

EQT Corporation

$62.56

-0.45 (-0.71%)

RICE

Rice Energy

$27.32

-0.2 (-0.73%)

EQGP

EQT GP

$29.71

-0.53 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 14

    Nov

  • 15

    May

  • 16

    May

NFLX

Netflix

$202.68

3.19 (1.60%)

05:12
10/17/17
10/17
05:12
10/17/17
05:12
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CMC

Commercial Metals

$20.50

-0.28 (-1.35%)

, GGB

Gerdau

$3.57

-0.01 (-0.28%)

05:11
10/17/17
10/17
05:11
10/17/17
05:11
Upgrade
Commercial Metals, Gerdau rating change  »

Commercial Metals…

CMC

Commercial Metals

$20.50

-0.28 (-1.35%)

GGB

Gerdau

$3.57

-0.01 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SECO

Seeco Holding

$8.30

0.14 (1.72%)

05:07
10/17/17
10/17
05:07
10/17/17
05:07
Initiation
Seeco Holding initiated  »

Seeco Holding initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$198.41

-7.11 (-3.46%)

05:06
10/17/17
10/17
05:06
10/17/17
05:06
Recommendations
Allergan analyst commentary  »

Allergan price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

EV

Eaton Vance

$51.10

0.03 (0.06%)

05:02
10/17/17
10/17
05:02
10/17/17
05:02
Initiation
Eaton Vance initiated  »

Eaton Vance initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$31.48

0.2 (0.64%)

05:02
10/17/17
10/17
05:02
10/17/17
05:02
Initiation
Federated Investors initiated  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

JHG

Janus Henderson Group

$35.22

-0.08 (-0.23%)

05:01
10/17/17
10/17
05:01
10/17/17
05:01
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$37.63

-1.11 (-2.87%)

05:01
10/17/17
10/17
05:01
10/17/17
05:01
Initiation
Legg Mason initiated  »

Legg Mason initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WETF

WisdomTree

$11.00

0.01 (0.09%)

05:00
10/17/17
10/17
05:00
10/17/17
05:00
Initiation
WisdomTree initiated  »

WisdomTree initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.27

0.52 (3.53%)

04:59
10/17/17
10/17
04:59
10/17/17
04:59
Downgrade
Freeport McMoRan rating change  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ERJ

Embraer

$21.42

-0.63 (-2.86%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

04:56
10/17/17
10/17
04:56
10/17/17
04:56
Downgrade
Embraer, Airbus rating change  »

Embraer downgraded to…

ERJ

Embraer

$21.42

-0.63 (-2.86%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$114.58

0.72 (0.63%)

, CSOD

Cornerstone OnDemand

$39.02

0.02 (0.05%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Stephens human capital management team holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$114.58

0.72 (0.63%)

CSOD

Cornerstone OnDemand

$39.02

0.02 (0.05%)

MSFT

Microsoft

$77.65

0.16 (0.21%)

ORCL

Oracle

$48.86

0.25 (0.51%)

PAYC

Paycom

$78.99

-0.9 (-1.13%)

PCTY

Paylocity

$50.08

0.17 (0.34%)

SAP

SAP

$111.84

-0.88 (-0.78%)

ULTI

Ultimate Software

$194.45

-3.47 (-1.75%)

WDAY

Workday

$107.23

-2.13 (-1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

  • 31

    Oct

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 05

    Nov

  • 08

    Nov

  • 15

    Nov

WES

Western Gas Partners

$50.92

-0.38 (-0.74%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Western Gas Partners to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Stephens food & agribusiness analyst holds an analyst/industry conference call »

Food & Agribusiness…

SFNC

Simmons First National

$58.90

0.45 (0.77%)

, OKSB

Southwest Bancorp

$28.05

0.15 (0.54%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Southwest Bancorp to host special shareholder meeting »

Special Shareholder…

SFNC

Simmons First National

$58.90

0.45 (0.77%)

OKSB

Southwest Bancorp

$28.05

0.15 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 23

    Oct

CLSD

Clearside Biomedical

$7.77

0.03 (0.39%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Clearside Biomedical management to meet with JMP Securities »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AKR

Acadia Realty Trust

$30.26

-0.2 (-0.66%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Acadia Realty Trust management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 03

    Nov

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Citigroup to hold a conference »

9th Annual Australian…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.